Cyclacel Pharmaceuticals Inc - Company Profile
Powered by
All the data and insights you need on Cyclacel Pharmaceuticals Inc in one report.
- Save hours of research time and resources with
our up-to-date Cyclacel Pharmaceuticals Inc Strategy Report
- Understand Cyclacel Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Cyclacel Pharmaceuticals Inc (Cyclacel) is a biopharmaceutical company that develops oral therapies. The company develops small molecule drugs that target various phases of cell cycle control for the treatment of cancer and other serious diseases. Its products include sapacitabine, seliciclib, PLK inhibitor and CDK inhibitor. Cyclacel’s sapacitabine is the drug candidate used to treat the patients with acute myeloid leukemia. The company’s seliciclib is an orally available, cyclin dependent kinase inhibitor. It offers products for the treatment of anti-infective, autoimmune, cardiovascular, ophthalmic and other non-oncology indications. The company operates in the US and the UK. Cyclacel is headquartered in Berkeley Heights, New Jersey, the US.
Cyclacel Pharmaceuticals Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
Fadraciclib CDK Inhibitor (Oral) - Solid Tumors, Leukemias |
Fadraciclib CDK Inhibitor (i.v.) - Solid Tumors, CLL, AML/MDS |
XYZ |
XYZ |
XYZ |
Competitor Comparison
Key Parameters | Cyclacel Pharmaceuticals Inc | Esperion Therapeutics Inc | Abeona Therapeutics Inc | GeneLink BioSciences, Inc. | Deltagen Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
City | Berkeley Heights | Vero Beach | Cleveland | Elmsford | Redwood City |
State/Province | New Jersey | Florida | Ohio | New York | California |
No. of Employees | 12 | 240 | 84 | 15 | 268 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Spiro Rombotis | President; Chief Executive Officer; Director | Executive Board | 2021 | 64 |
Paul McBarron | Chief Operating Officer; Executive Vice President - Finance; Secretary; Director | Executive Board | 2021 | 62 |
Brian Schwartz, M.D. | Chief Medical Officer - Interim | Senior Management | 2024 | - |
Christopher S. Henney, Ph.D. | Chairman | Non Executive Board | 2005 | 82 |
Robert J. Spiegel, M.D | Vice Chairman | Senior Management | 2018 | 73 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward